Geode Capital Management LLC Raises Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX)

Geode Capital Management LLC lifted its holdings in shares of Nkarta, Inc. (NASDAQ:NKTX) by 3.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,171,026 shares of the company’s stock after buying an additional 33,927 shares during the quarter. Geode Capital Management LLC’s holdings in Nkarta were worth $5,294,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Wasatch Advisors LP increased its stake in shares of Nkarta by 31.7% during the third quarter. Wasatch Advisors LP now owns 1,834,680 shares of the company’s stock worth $8,293,000 after purchasing an additional 442,125 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Nkarta by 11,164.3% during the second quarter. Acadian Asset Management LLC now owns 303,461 shares of the company’s stock valued at $1,792,000 after acquiring an additional 300,767 shares during the last quarter. Marshall Wace LLP lifted its position in shares of Nkarta by 136.7% in the second quarter. Marshall Wace LLP now owns 439,973 shares of the company’s stock valued at $2,600,000 after acquiring an additional 254,104 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Nkarta in the second quarter worth approximately $1,489,000. Finally, Affinity Asset Advisors LLC purchased a new stake in shares of Nkarta during the second quarter worth approximately $1,182,000. Hedge funds and other institutional investors own 80.54% of the company’s stock.

Nkarta Price Performance

Nkarta stock opened at $2.50 on Friday. The firm has a 50 day simple moving average of $2.70 and a 200-day simple moving average of $4.41. The stock has a market cap of $176.42 million, a price-to-earnings ratio of -1.33 and a beta of 0.82. Nkarta, Inc. has a 1-year low of $2.08 and a 1-year high of $16.24.

Wall Street Analysts Forecast Growth

NKTX has been the topic of a number of research reports. Needham & Company LLC decreased their price objective on Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Rodman & Renshaw began coverage on shares of Nkarta in a research report on Wednesday, October 9th. They set a “buy” rating and a $14.00 price target on the stock. HC Wainwright dropped their price objective on shares of Nkarta from $22.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, November 11th. RODMAN&RENSHAW raised shares of Nkarta to a “strong-buy” rating in a research note on Wednesday, October 9th. Finally, Mizuho dropped their price target on Nkarta from $20.00 to $16.00 and set an “outperform” rating for the company in a research report on Thursday, November 21st. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $15.00.

Nkarta Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.